×
About 20,240 results

Selenium Supplementation of Patients With Cirrhosis
https://clinicaltrials.gov/ct2/show/NCT00212186

Mar 6th, 2012 - Selenium is an essential nutrient. Selenium carries out its biological functions through selenoproteins. The most abundant selenoprotein in the plasma is selenoprotein P, which is largely synthesized in the liver. Patients with liver disease often have less than half the selenoprotein P levels of normal individuals. This suggests that people with liver disease are not meeting their selenium req...

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
https://clinicaltrials.gov/ct2/show/NCT00005042

Aug 28th, 2014 - OBJECTIVES: I. Determine the antitumor effects of SU5416 in patients with chemotherapy refractory cutaneous AIDS-related Kaposi's sarcoma. II. Determine the safety and tolerability of this regimen in these patients. III. Determine the pharmacokinetics of this regimen in these patients. IV. Determine the safety of this regimen on HIV replication and immune parameters in these patients. V. Determ...

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00019539

Jun 19th, 2013 - OBJECTIVES: I. Determine the effect of monoclonal antibody VEGF on time to progression, angiogenesis, and overall survival in patients with unresectable advanced renal cell cancer. II. Evaluate serum antibody levels and biologically active vascular endothelial growth factor levels in the plasma of patients treated with this regimen. III. Evaluate the toxicity of this regimen in these patients. ...

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
https://clinicaltrials.gov/ct2/show/NCT00107432

Jun 4th, 2013 - PRIMARY OBJECTIVES: I. To determine the response rate (partial response (PR) and complete response (CR)) in patients with malignant mesothelioma treated with BAY 43-9006. SECONDARY OBJECTIVES: I. To determine 3-month failure free survival in patients with malignant mesothelioma treated with BAY 43-9006. II. To describe the median and overall survival of malignant mesothelioma patients treated w...

Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
https://clinicaltrials.gov/ct2/show/NCT00006245

Jun 23rd, 2013 - OBJECTIVES: Determine the response rate in patients with paclitaxel-refractory locally advanced or metastatic esophageal cancer treated with sequential paclitaxel and flavopiridol. Determine the toxicity of this regimen in these patients. Assess the quality of life of patients treated with this regimen. Obtain pharmacokinetic information about this regimen. OUTLINE: This is a multicenter study....

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
https://clinicaltrials.gov/ct2/show/NCT00006006

Feb 10th, 2013 - OBJECTIVES: I. Determine the feasibility and activity of thalidomide in patients with unresectable hepatocellular carcinoma. II. Evaluate the toxicity of thalidomide in these patients. III. Assess the use of interferon alfa in patients who develop disease progression while being treated with thalidomide. OUTLINE: This is a multicenter study. Patients receive oral thalidomide once daily. Patient...

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions
https://clinicaltrials.gov/ct2/show/NCT00601328

Jan 22nd, 2018 - The objective of this study was to assess the bioequivalence of Roxane Laboratories' Calcitriol capsules, 0.25 mcg, to ROCALTROL® capsules, 0.25 mcg (Roche) using a single-dose, 2-treatment, 2-period, crossover design, under fasting conditions

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT00150657

Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible. Patients with brain metastases, squamous histology, or hemoptysis are excluded. All patients must give informed consent. Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg ...

Validation of 18F-MISO-PET and 18F-FLT-PET
https://clinicaltrials.gov/ct2/show/NCT00159978

May 6th, 2015 - Hypoxia and tumor cell proliferation are important mechanisms contributing to resistance to radiotherapy in human head and neck tumor cells. Currently, assessment of these two tumor characteristics is performed in biopsies using immunohistochemical staining and subsequent analysis. A promising non-invasive method of characterizing a tumor is the use of positron-emission tomography (PET). Specif...

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00393796

Nov 12th, 2014 - This study is a randomized, blinded, placebo-controlled study evaluating the drug, SUO11248 (SUTENT), for maintenance therapy in advanced urothelial cancer.

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
https://clinicaltrials.gov/ct2/show/NCT00380263

May 29th, 2008 - To investigate headache score and accompanying symptoms during and after infusion of PACAP38 Changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), blood flow in MCA, diameter of the superficial temporal artery (STA) and radial artery (RA)

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
https://clinicaltrials.gov/ct2/show/NCT00609804

Apr 7th, 2016 - This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.

Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma
https://clinicaltrials.gov/ct2/show/NCT01579344

The radioactive radioiodine therapy (Na131I) for the treatment of differentiated thyroid carcinoma is a procedure used for ablation of remaining thyroid tissue after thyroidectomy and metastases. Although serious complications are uncommon after treatment, there are well-documented adverse reactions secondary to the involvement of the salivary glands, such as dry mouth, pain in the parotid glan...

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02176720

Aug 16th, 2018 - Malignant gliomas are aggressive primary brain tumors that almost always lead to rapid patient deterioration and death. Timely diagnosis of recurrent disease as well as accurate monitoring of therapeutic responses is critically important in glioblastoma patients. Despite introduction of new treatment approaches patient prognosis is poor with less than half of the patients being progression-free...

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy
https://clinicaltrials.gov/ct2/show/NCT01200264

Jul 14th, 2014 - Data Analysis Data will be analyzed and reported after all subjects have completed follow-up phase of study. All subsequent data collected will be analyzed and reported in a follow-up clinical report. Data & Safety Monitoring Dr. Murray will be following all laboratory values and adverse events during this trial. In addition, Celgene will provide a study monitor to, at regular intervals, review...

A Nutritional Intervention for Arthritis
https://clinicaltrials.gov/ct2/show/NCT01544101

Oct 18th, 2012 - Preliminary evidence suggests that low-fat, vegetarian diets and certain nutritional supplements can help reduce pain and also reduce the need for pain medications for some people. The investigators will ask about 100 people to participate. All of them will get a low-fat, vegan diet and a nutritional supplement (mixture of omega-3 oils and vitamin E or a placebo), although some will get the die...

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT01222195

Aug 6th, 2012 - The goal of this clinical research study is to learn if lenalidomide and darbepoetin alfa given together will help to control the need for transfusions in patients with low to intermediate risk Myelodysplastic Syndrome (MDS). The safety of this combination will also be studied.

Ranibizumab for Myopic Neovascularization
https://clinicaltrials.gov/ct2/show/NCT01246089

Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of pers...

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
https://clinicaltrials.gov/ct2/show/NCT01246076

Jan 4th, 2016 - The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.

Vitamin E and Male Infertility
https://clinicaltrials.gov/ct2/show/NCT00178516

Jul 29th, 2009 - Sperm DNA damage is an emerging cause of male infertility that is likely to be more common among men with increased reactive oxygen species in the ejaculate. Vitamin E can protect the sperm membrane from oxidative damage and increased levels are associated with low levels of reactive oxygen species. This is a study of Vitamin E levels in the spermatozoa and sera of 48 infertile men, and 20 fert...